We are live on
!
Find out more
Frazier Life Sciences Management Portfolio holdings
AUM
$4.59B
Turnover
20.45%
1-Year Est. Return
237.58%
This Fund
S&P 500
This Quarter
Est. Return
+29.57%
1 Year Est. Return
+237.58%
3 Year Est. Return
+865.83%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.61B
AUM Growth
+$310M
(+24%)
Cap. Flow
+$124M
Cap. Flow
% of AUM
7.72%
Top 10 Holdings %
Top 10 Hldgs %
66.37%
Holding
50
New
7
Increased
9
Reduced
5
Closed
6
Avg Time Held
0.6
years
Top 10 Avg Time Held
0.6
years
Top 20 Avg Time Held
0.6
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NewAmsterdam Pharma
NAMS
|
+$92.8M |
| 2 |
IMGO
Imago BioSciences, Inc. Common stock
IMGO
|
+$25.4M |
| 3 |
VECT
VectivBio Holding AG Ordinary Shares
VECT
|
+$10.7M |
| 4 |
VRNA
Verona Pharma
VRNA
|
+$9.54M |
| 5 |
KalVista Pharmaceuticals
KALV
|
+$8.93M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TCDA
Tricida, Inc. Common Stock
TCDA
|
+$26.7M |
| 2 |
FLACU
Frazier Lifesciences Acquisition Corporation Unit
FLACU
|
+$15.2M |
| 3 |
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
|
+$9.31M |
| 4 |
Vaxcyte
PCVX
|
+$5.89M |
| 5 |
MacroGenics
MGNX
|
+$2.43M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.97% |
| 2 | Miscellaneous | 0.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
DELISTED
HilleVax
HLVX
| $163M | 10.15% |
9,758,359
| – | – |
2022 Q2
2 quarters
|
|
|
IMGO
2
DELISTED
Imago BioSciences, Inc. Common stock
IMGO
| $143M | 8.91% |
3,987,207
+1,015,933
| +34% | +$25.4M |
2022 Q1
3 quarters
|
|
3
Arcutis Biotherapeutics
ARQT
$3.32B
| $129M | 7.99% |
8,684,232
| – | – |
2022 Q1
3 quarters
|
|
|
KDNY
4
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $114M | 7.08% |
4,345,559
+80,000
| +2% | +$1.77M |
2022 Q1
3 quarters
|
|
|
5
NewAmsterdam Pharma
NAMS
$2.39B
| $102M | 6.33% |
+9,341,551
| New | +$92.8M |
2022 Q4
0 quarters
|
|
6
Syndax Pharmaceuticals
SNDX
$1.21B
| $94.4M | 5.87% |
3,708,838
+296,000
| +9% | +$6.9M |
2022 Q1
3 quarters
|
|
7
Phathom Pharmaceuticals
PHAT
$599M
| $94.3M | 5.86% |
8,407,152
| – | – |
2022 Q1
3 quarters
|
|
8
Krystal Biotech
KRYS
$9.79B
| $79.2M | 4.92% |
999,737
-18,651
| -2% | -$1.38M |
2022 Q1
3 quarters
|
|
9
Mirum Pharmaceuticals
MIRM
$5.19B
| $75.3M | 4.68% |
3,860,107
+32,326
| +0.8% | +$639K |
2022 Q1
3 quarters
|
|
|
VRNA
10
DELISTED
Verona Pharma
VRNA
| $73.6M | 4.57% |
2,815,720
+716,179
| +34% | +$9.54M |
2022 Q3
1 quarter
|
|
|
11
Vaxcyte
PCVX
$10.6B
| $67M | 4.17% |
1,397,405
-150,000
| -10% | -$5.89M |
2022 Q1
3 quarters
|
|
12
Rhythm Pharmaceuticals
RYTM
$5.97B
| $55.2M | 3.43% |
1,894,000
| – | – |
2022 Q3
1 quarter
|
|
13
DELISTED
Allakos
ALLK
| $40.3M | 2.51% |
4,792,000
| – | – |
2022 Q3
1 quarter
|
|
14
AnaptysBio
ANAB
$1.4B
| $27.9M | 1.73% |
899,700
| – | – |
2022 Q1
3 quarters
|
|
15
Tarsus Pharmaceuticals
TARS
$3.38B
| $26.2M | 1.63% |
1,787,527
| – | – |
2022 Q1
3 quarters
|
|
16
DELISTED
Crinetics Pharmaceuticals
CRNX
| $25.9M | 1.61% |
1,414,823
| – | – |
2022 Q1
3 quarters
|
|
17
Replimune Group
REPL
$1.07B
| $25.3M | 1.58% |
931,560
+125,293
| +16% | +$2.6M |
2022 Q1
3 quarters
|
|
18
Cogent Biosciences
COGT
$4.88B
| $24.4M | 1.52% |
2,109,154
+35,000
| +2% | +$434K |
2022 Q1
3 quarters
|
|
19
DELISTED
Alpine Immune Sciences Inc
ALPN
| $21.9M | 1.36% |
2,985,757
| – | – |
2022 Q1
3 quarters
|
|
|
20
DELISTED
KalVista Pharmaceuticals
KALV
| $21.9M | 1.36% |
3,238,859
+1,666,667
| +106% | +$8.93M |
2022 Q1
3 quarters
|
|
21
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $17.8M | 1.11% |
5,162,348
-75,000
| -1% | -$214K |
2022 Q1
3 quarters
|
|
22
Sutro Biopharma
STRO
$174M
| $14.4M | 0.89% |
177,648
| – | – |
2022 Q1
3 quarters
|
|
23
Acadia Pharmaceuticals
ACAD
$3.32B
| $13.6M | 0.85% |
857,338
| – | – |
2022 Q3
1 quarter
|
|
24
Silence Therapeutics
SLN
$558M
| $13.4M | 0.84% |
881,173
| – | – |
2022 Q1
3 quarters
|
|
25
Trevi Therapeutics
TRVI
$1.72B
| $12.9M | 0.8% |
6,663,590
+1,260,000
| +23% | +$2.48M |
2022 Q2
2 quarters
|
|
Similar funds
BWA
TYCC
Frazier Life Sciences Management's Q4 2022 Portfolio in Review
As of Q4 2022, Frazier Life Sciences Management held 50 positions worth $1.61B, up 24% from $1.3B the previous quarter. Its ten largest holdings account for 66% of the portfolio.
Frazier Life Sciences Management deployed $124M of net new capital in Q4 2022, opening 7 new positions and adding to 9 existing holdings. Its largest new stake was NewAmsterdam Pharma: 9,341,551 shares worth $102M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Vaxcyte, an estimated $5.89M trimmed.
- Frazier Life Sciences Management's largest Q4 2022 buy was NewAmsterdam Pharma: 9,341,551 shares worth $102M.
- Frazier Life Sciences Management added most to Imago BioSciences, Inc. Common stock in Q4 2022, an estimated $25.4M increase.
- Frazier Life Sciences Management's biggest Q4 2022 reduction was Vaxcyte, cutting an estimated $5.89M.
- Frazier Life Sciences Management fully exited Tricida, Inc. Common Stock in Q4 2022, selling an estimated $26.7M.
- Frazier Life Sciences Management's ten largest holdings make up 66% of its $1.61B portfolio in Q4 2022.
- Frazier Life Sciences Management opened 7 new positions and closed 6 in Q4 2022.
- Frazier Life Sciences Management's portfolio value rose 24% quarter-over-quarter to $1.61B.
Based on Frazier Life Sciences Management's 13F filing for Q4 2022, filed 3 Feb 2023.